Treatment modifiers and predictors of risperidone response in dementia: An individual participant data meta‐analysis of six randomized controlled trials
Risperidone modestly reduces symptoms of psychosis, aggression, and anxiety/phobias. Risperidone shows no effect on activity, affective, or sleep disturbances. Patient factors (body mass index, endocrine disease, race/ethnicity) may affect response. Positive response by week 2 predicts significant improvement later.
Authors
- Sarah Nicole Hilmer (ORCID: https://orcid.org/0000-0002-5970-1501)
- Tuan Anh Nguyen (ORCID: https://orcid.org/0000-0002-9528-9278)
- Edward C Y Lau (ORCID: https://orcid.org/0009-0005-5712-2337)
- Edwin C.K. Tan (ORCID: https://orcid.org/0000-0003-2922-8837)
- Trong Hieu Le (ORCID: https://orcid.org/0000-0001-6812-7778)
- Lee‐Fay Low (ORCID: https://orcid.org/0000-0001-9283-3525)
- Yun‐Hee Jeon (ORCID: https://orcid.org/0000-0003-2031-9134)
- Christine Y. Lu (ORCID: https://orcid.org/0000-0002-7550-6837)
Institutions
- The University of Sydney (AU)
- University of South Australia (AU)
- Royal North Shore Hospital (AU)
- UNSW Sydney (AU)
- National Ageing Research Institute (AU)
- Northern Sydney Local Health District (AU)
- Swinburne University of Technology (AU)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/alz.70665
- Citations
- 1
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Yale University
- University of Sydney